In the present report, increase in LDL fraction due to altered PCSK9 level or hypercholesterolemia (independent of PCSK9 signaling) would increase the probability of sorafenib binding to LDL, thus reducing the fraction of drug available for uptake by the tumor cells. This evidence concerns the gene PCSK9 and neoplasm.